Health Regulators Issue Warning for Onglyza

The Irish Medicines Board and the European Medicines Agency issued a warning for the blood sugar lowering drug Onglyza (saxagliptin) because it was linked to severe adverse side-effects.

According to The Evening Herald, the drug’s manufacturers Bristol-Myers Squibb and AstraZeneca received reports of patients experiencing “serious hypersensitivity reactions,” such as acute pancreatic and anaphylactic shock. They asked medical professionals to avoid prescribing Onglyza for patients who have a history of these types of reactions as well as patients with suspected inflammation of the pancreas.

There was evidence that “signs of pancreatitis occurred after the start of saxagliptin treatment” but stopped when the patient discontinued using the drug.

The drugmakers updated the information for Onglyza to reflect the new findings.

If you or a loved one has been harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you.